Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152281 | 0.76 | CCNB2 (0.54) | HTR5ACDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL29622074 | 0.76 | CCNB2 (0.54) | HTR5ACDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL9833949 | 0.76 | MEN1 (0.48) | HTR5ACDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL9924225 | 0.76 | GABRA1 (0.36) | CYP1A2CA1CA2 | |
| SCHEMBL5141694 | 0.74 | NPC1 (0.47) | HTR5ACDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL20777511 | 0.74 | HTR5A (0.52) | HTR5ACDK5CDK5R1CREBBPPARP1 | |
| SCHEMBL25609629 | 0.72 | PRCP (0.40) | CREBBPPARP10PARP11BRD4ALDH1A1 | |
| SCHEMBL19657830 | 0.68 | BRD4 (0.56) | HTR5ACDK5CDK5R1CREBBPPARP1 | |
| SCHEMBL19142696 | 0.68 | HTR5A (0.47) | HTR5ACREBBPGRIA1CACNG8ALDH1A1 | |
| SCHEMBL22067622 | 0.68 | DRD2 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| WO-2020244613-A1 | 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR KINASE INHIBITOR | 北京泰德制药股份有限公司 | 2020-12-10 | — | — | WO | disclosed |
| EP-3252038-A1 | N-BENZOATE GROUP SUBSTITUTED BENZOPYRROLINE-2-ONE DERIVATIVE AND USE THEREOF | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-06 | — | — | EP | disclosed |
| EP-2046799-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160220702-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE BIOSCIENCE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20150216857-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150182520-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150174119-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-9051297-B2 | Compositions and methods for treatment | SARCODE BIOSCIENCE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150140080-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150140078-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150140076-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20140378506-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140371265-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8771715-B2 | Compositions and methods for treatment | SARCODE BIOSCIENCE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140141062-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140073666-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20120232019-A1 | Compositions and Methods for Treatment of Eye Disorders | SARCODE BIOSCIENCE INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20110165228-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378506-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20110165228-A1 | Compositions and Methods for Treatment | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20140371265-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20150216857-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20140073666-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20150140080-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20150140078-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20150182520-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20160220702-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | VCAM1, ITGB1, ICAM1 | HTR5A 833/4885CDK5 1369/4885CDK5R1 694/4885 |
| US-20150174119-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20150140076-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
| US-20120232019-A1 | Compositions and Methods for Treatment of Eye Disorders | ICAM1, VCAM1, ITGAL | HTR5A 647/4885CDK5 2547/4885CDK5R1 1683/4885 |
| US-20140141062-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HTR5A 617/4885CDK5 2547/4885CDK5R1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.